Quinoxalin-2(1H)-one baseddesign and synthesis produced several series of aldose reductase (ALR2) inhibitor candidates. In particular, phenolic structure was installed in the compounds for the combination of antioxidant activity and strengthening the ability to fight against diabetic complications. Most of the series 6 showed potent and selective effects on ALR2 inhibition with IC50 values in the
A group of novel quinoxalinone derivatives (4a–h) were prepared and investigated for their inhibitory activity against ALR2 and antioxidant activity. Most of them were found to be potent aldosereductaseinhibitors with IC50 values ranging from 0.019 to 0.982 μM. The most active compound 2-(3-(4-hydroxyphenoxy)-6-fluoro-2-oxoquinoxalin-1(2H)-yl)acetic acid (4c) also had an excellent selectivity. In
quinoxalinone derivatives were synthesized and tested for their inhibitory activity against aldosereductase. Among them, N1-acetate derivatives had significant activity in a range of IC50 values from low micromolar to submicromolar, and compound 15a bearing a C3-phenethyl side chain was identified as the most potent inhibitor with an IC50 value of 0.143 μM. The structure–activitystudies suggested that
Synthesis and Structure-Activity Relationship Studies of Quinoxaline Derivatives as Aldose Reductase Inhibitors
作者:Bobin Wu、Yanchun Yang、Xiangyu Qin、Shuzhen Zhang、Chaojun Jing、Changjin Zhu、Bing Ma
DOI:10.1002/cmdc.201300324
日期:2013.12
ARIs for diabetes: A series of 2‐(3‐benzyl‐2‐oxoquinoxalin‐1(2H)‐yl)acetic acid derivatives were designed and synthesized as inhibitors of aldosereductase (AR), a novel target for the treatment of diabetes complications. Most of the derivatives proved to be potent and selective, with IC50 values in the low nanomolar to micromolar range.
of quinoxalinone‐based aldose reductase inhibitors were synthesized successfully. Most of the inhibitors, with an N1‐acetic acid head group and a substituted C3‐phenoxy side chain, proved to be potent and selective. Their IC50 values ranged from 11.4 to 74.8 nM. Among them, 2‐(3‐(4‐bromophenoxy)‐7‐fluoro‐2‐oxoquinoxalin‐1(2H)‐yl)acetic acid and 2‐(6‐bromo‐3‐(4‐bromophenoxy)‐2‐oxoquinoxalin‐1(2H)‐yl)acetic